Notable Quotes

"There is opportunity for the FDA to accept a new drug application filing from SNSS."
(1/27/15)
Sunesis Pharmaceuticals Inc.
-
The Life Sciences Report Interview with Mara Goldstein
More >

"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity."
(1/22/15)
Neuralstem Inc.
-
The Life Sciences Report Interview with Edward Stopke
More >

"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E."
(1/22/15)
Athersys Inc.
-
The Life Sciences Report Interview with Edward Stopke
More >

"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential."
(1/22/15)
Rexahn Pharmaceuticals Inc.
-
The Life Sciences Report Interview with Edward Stopke
More >

Companies

TICKER: TKMR:NASDAQ; TKM:TSX

A summary of Expert Comments about Tekmira Pharmaceuticals Inc. is currently unavailable. You can find Expert Comments on companies similar to Tekmira Pharmaceuticals Inc. by clicking on the links below.